is retatrutide approved 2025 the most significant weight-loss pharmaceutical currently in clinical development. Phase 3 TRIUMPH-4 trial results (published December 2025) showed average body weight reduction of 28.7% at 68 weeks — approaching outcomes Retatrutide Promises Big Weight Loss,

Cytokine Growth Factor Rev

Semaglutide activates only GLP-1 receptors, while tirzepatide (a GLP-1/GIP receptor agonist) engages dual pathways, often producing faster or more substantial weight lossup to 22% in clinical trials versus 15% for semaglutide alone

Evaluation of serum oxidative stress levels and antioxidant capacity in prediabetes

Statistics Two-sided TukeyKramer multiple comparison test was used for statistical analysis 10,45

Products marketed online as retatrutide may be counterfeit, mislabeled, adulterated, improperly compounded, or not manufactured under the standards required for approved human medications

Until supply issues have resolved, clinicians are being advised to avoid initiating people with type 2 diabetes on GLP-1 RAs